Maarten Te Groen

Maarten Te Groen

Auto-generated profile, based on publicly available information

Maarten Te Groen

Inflammatory Bowel Disease Centre, Department of Gastroenterology and Hepatology, Radboudumc, Nijmegen, The Netherlands

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2022 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Open access
MGMaarten Te Groen
Maarten Te Groen
MDMonica Derks
Monica Derks
NBNathan Den Broeder
Nathan Den Broeder
CPCharlotte Peters
Charlotte Peters
GDGerard Dijkstra
Gerard Dijkstra
FHFrank Hoentjen
Frank Hoentjen
Although colorectal cancer (CRC) surveillance is embedded in clinical inflammatory bowel disease (IBD) practice, a subset of patients still develops advanced neoplasia (AN) (high-grade dysplasia [HGD] and/or CRC). We aimed to assess the impact of surveillance quality on AN risk in IBD. In this multicenter case-control study, we searched the Dutch nationwide pathology databank to identify IBD cases with AN and controls with indefinite or low-grade dysplasia. The surveillance colonoscopy preceding the index lesion (first indefinite for dysplasia [IND]/low-grade dysplasia [LGD] or AN) was used to assess the impact of surveillance quality. We assessed intervals, bowel preparation, cecal intubation, and absence of inflammation as primary quality indicators. In addition, we assessed chromoendoscopy, endoscopist expertise, hospital setting, and biopsy strategy. Associations of quality indicators with AN risk were determined with multivariable logistic regression analyses with Firth's correction. We included 137 cases and 138 controls. Delayed intervals (58.2% vs 39.6%) and active inflammation (65.3% vs 41.8%) were frequently present in cases and controls and were associated with AN (delayed interval: adjusted odds ratio [aOR], 2.00; 95% confidence interval [CI], 1.07-3.81; P = .03; active inflammation: aOR, 2.46; 95% CI, 1.33-4.61; P < .01). Surveillance compliant with primary quality indicators was associated with a reduced AN risk (aOR, 0.43; 95% CI, 0.22-0.91; P = .03), similar to chromoendoscopy (OR, 0.11; 95% CI, 0.01-0.89; P = .01). Other indicators were not significantly associated with AN. Surveillance compliant with primary quality indicators is associated with a reduced colitis-associated AN risk. Delayed surveillance intervals and active inflammation were associated with an increased AN risk. This underlines the importance of procedural quality, including endoscopic remission to optimize the effectiveness of endoscopic surveillance.

16 January 2025 in Gut
Verified
Journal Article
Closed access
PDF file
MGMaarten Te Groen
Maarten Te Groen
AWAnouk M Wijnands
Anouk M Wijnands
NBNathan Den Broeder
Nathan Den Broeder
DJDirk J de Jong
Dirk J de Jong
WDWillemijn A van Dop
Willemijn A van Dop
DCDutch Initiative On Crohn And Colitis
Dutch Initiative On Crohn And Colitis
Background It remains unclear if the increased colorectal neoplasia detection rate in inflammatory bowel disease (IBD) by high-definition (HD) dye-based chromoendoscopy compared with HD white-light endoscopy is due to enhanced contrast or increased inspection times. Longer withdrawal times may yield similar neoplasia detection rates as found by HD chromoendoscopy. Objective To compare colorectal neoplasia detection rates for HD white-light endoscopy with segmental re-inspection and HD chromoendoscopy, using single-pass HD white-light endoscopy as an additional control group. Design In a multicentre, randomised controlled trial, IBD patients aged ≥18 years without active disease and scheduled for endoscopic surveillance were included. Patients were 2:2:1 randomised to HD white-light endoscopy with segmental re-inspection of each colonic segment (double pass), HD chromoendoscopy or single-pass HD white-light endoscopy. The primary outcome was colorectal neoplasia detection rate. Assuming equal colorectal neoplasia rates (non-inferiority margin of 10%) between segmental re-inspection and chromoendoscopy and superiority of segmental re-inspection vs single-pass HD white-light endoscopy, a sample size of 566 patients was required. Results In total, 563 patients were analysed per-protocol. Colorectal neoplasia detection rates were 10.3% (n=24/234) for HD white-light endoscopy with segmental re-inspection and 13.1% (n=28/214) for HD chromoendoscopy. This confirmed non-inferiority to HD chromoendoscopy (Δ−2.8%, lower limit 95% CI −7.8, p<0.01). In addition, the number of detected colorectal neoplasia per 10 min of withdrawal time was similar between HD white-light endoscopy with segmental re-inspection and HD chromoendoscopy (0.062 vs 0.058, p=0.83). Single-pass HD white-light endoscopy yielded a lower colorectal neoplasia rate (6.1%; n=7/115) than segmental re-inspection but this was not statistically significant (Δ4.1%, 95% CI −2.2:9.6%, p=0.19). Conclusions HD white-light endoscopy with segmental re-inspection was non-inferior to HD chromoendoscopy for colorectal neoplasia detection in IBD patients. It can therefore be assumed that the benefit of HD chromoendoscopy may be explained by the longer withdrawal time and not necessarily the enhanced contrast. However, re-inspection per se did not lead to a significantly higher colorectal neoplasia rate than single-pass HD white-light endoscopy alone.

1 February 2021 in Gastroenterology
Verified
Journal Article
Open access
MGMaarten Te Groen
Maarten Te Groen
MDMonica E.W. Derks
Monica E.W. Derks
CKChantal C.H. J. Kuijpers
Chantal C.H. J. Kuijpers
INIris D. Nagtegaal
Iris D. Nagtegaal
FHFrank Hoentjen
Frank Hoentjen

14 May 2024 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
PDF file
MDMonica E W Derks
Monica E W Derks
MGMaarten Te Groen
Maarten Te Groen
LLLisa M A van Lierop
Lisa M A van Lierop
SMSanjay Murthy
Sanjay Murthy
DRDavid T Rubin
David T Rubin
FHFrank Hoentjen
Frank Hoentjen
Inflammatory bowel disease [IBD] patients are at increased risk of developing colorectal neoplasia [CRN]. In this review, we aim to provide an up-to-date overview and future perspectives on CRN management in IBD. Advances in endoscopic surveillance and resection techniques have resulted in a shift towards endoscopic management of neoplastic lesions in place of surgery. Endoscopic treatment is recommended for all CRN if complete resection is feasible. Standard [cold snare] polypectomy, endoscopic mucosal resection and endoscopic submucosal dissection should be performed depending on lesion complexity [size, delineation, morphology, surface architecture, submucosal fibrosis/invasion] to maximise the likelihood of complete resection. If complete resection is not feasible, surgical treatment options should be discussed by a multidisciplinary team. Whereas [sub]total and proctocolectomy play an important role in management of endoscopically unresectable CRN, partial colectomy may be considered in a subgroup of patients in endoscopic remission with limited disease extent without other CRN risk factors. High synchronous and metachronous CRN rates warrant careful mucosal visualisation with shortened intervals for at least 5 years after treatment of CRN.

27 October 2020 in Journal of Neurology
Verified
Journal Article
Open access
PDF file
MGMaarten Te Groen
Maarten Te Groen
BBBastiaan R. Bloem
Bastiaan R. Bloem
SWSamuel S. Wu
Samuel S. Wu
BPBart Post
Bart Post
TIThe Parkinson’s Foundation Quality Improvement Initiative investigators
The Parkinson’s Foundation Quality Improvement Initiative investigators
Background: Parkinson’s disease (PD) is typically considered as a disease of the elderly. However, there is a sizeable subgroup of patients where PD starts at a younger age, known as young-onset PD (YOPD). We evaluated the differences in quality of life and caregiver strain between YOPD and later onset PD (LOPD) patients in a large cohort.Methods: In collaboration with the Parkinson Foundation Quality Improvement Initiative (PF-QII), we conducted a retrospective three-year analysis on 962 PD patients of the QII database (starting date May 2016). Of these, 272 patients had YOPD, and 690 had LOPD. The Parkinson’s Disease Questionnaire-39 (PDQ-39) total score served as primary outcome measure. Furthermore, we analysed group differences in modified caregiver strain index (MCSI) total score, three cognition functions, and number of falls. A regression analysis adjusting for covariates was used to assess the association of age at onset with PDQ-39 and MCSI.Results: PDQ scores were better in YOPD patients, MCSI scores on social constraint were lower in YOPD patients, but scores on financial constraint were higher in this group. After adjusting for covariates, YOPD patients had better quality of life and less caregiver strain at all follow-up moments, but not at baseline. Decline over time for all outcomes was lower in the YOPD group compared to the LOPD group. Cognitive functioning and number of falls progressed slower in the YOPD group compared to the LOPD group.Conclusion: Compared to LOPD patients, YOPD patients had a better quality of life, less caregiver strain, fewer falls and better cognitive functioning after their first follow-up visit, and also a slower decline over time.

8 June 2023 in International Journal of Surgery
Verified
Journal Article
Open access
MDMonica Ew Derks
Monica Ew Derks
MGMaarten Te Groen
Maarten Te Groen
CPCharlotte P Peters
Charlotte P Peters
GDGerard Dijkstra
Gerard Dijkstra
AVAnnemarie C de Vries
Annemarie C de Vries
DCDutch Initiative On Crohn And Colitis
Dutch Initiative On Crohn And Colitis
Background: Inflammatory bowel disease (IBD) patients are at increased risk of advanced neoplasia (high-grade dysplasia (HGD) or colorectal cancer (CRC)). We aimed to (1) assess synchronous and metachronous neoplasia following (sub)total or proctocolectomy, partial colectomy or endoscopic resection for advanced neoplasia in IBD and (2) identify factors associated with treatment choice. Material and methods: In this retrospective multicenter cohort study, we used the Dutch nationwide pathology databank (PALGA) to identify patients diagnosed with IBD and colonic AN between 1991 and 2020 in seven hospitals in the Netherlands. Logistic and Fine&Gray’s subdistribution hazard models were used to assess adjusted subdistribution hazard ratios (asHR) for metachronous neoplasia and associations with treatment choice. Results: We included 189 patients (HGD n=81; CRC n=108). Patients were treated with proctocolectomy (n=33), (sub)total colectomy (n=45), partial colectomy (n=56) and endoscopic resection (n=38). Partial colectomy was more frequently performed in patients with limited disease and older age, with similar patient characteristics between Crohn’s disease and ulcerative colitis. Synchronous neoplasia was found in 43 patients (25.0%; (sub)total or proctocolectomy n=22, partial colectomy n=8, endoscopic resection n=13). We found a metachronous neoplasia rate of 6.1, 11.5 and 13.7 per 100 patient-years after (sub)total colectomy, partial colectomy and endoscopic resection, respectively. Endoscopic resection, but not partial colectomy, was associated with an increased metachronous neoplasia risk (asHR 4.16, 95% CI 1.64-10.54, P<0.01) compared to (sub)total colectomy. Conclusion: After confounder adjustment, partial colectomy yielded a similar metachronous neoplasia risk compared to (sub)total colectomy. High metachronous neoplasia rates after endoscopic resection underline the importance of strict subsequent endoscopic surveillance. Export